Sean P. Nolan
Chairman of the Board
Sean is chairman of the board of directors of Affinia Therapeutics. Previously, he served as chief executive officer of the gene therapy company AveXis until its acquisition by Novartis for $8.7 billion. Sean took the company through an IPO and built it into a fully integrated global organization with research, clinical, regulatory, manufacturing, and commercial capabilities. He was previously chief business officer of InterMune, chief commercial officer of Reata and Ovation Pharmaceuticals, and president of Lundbeck’s U.S. affiliate. Sean serves as executive chairman of Jaguar Gene Therapy, and is a board member of Encoded Therapeutics, Itsari Oncology, Taysha, and Ventas. He received a B.A. in biology from John Carroll University.